In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites

Robert J. Kazragis, Lisa L. Dever, James H. Jorgensen, Alan G. Barbour

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Borrelia burgdorferi, the agent of Lyme disease, and B. toricatae, a neurotropic agent of relapsing fever, are susceptible to vancomycin in vitro, with an MIC of 0.5 μg/ml. To determine the activity of vancomycin in vivo, particularly in the brain, we infected adult immunocompetent BALB/c and immunodeficient CB-17 scid mice with B. burgdorferi or B. turicatae. The mice were then treated with vancomycin, ceftriaxone as a positive control, or normal saline as a negative control. The effectiveness of treatment was assessed by cultures of blood and brain and other tissues. Ceftriaxone at a dose of 25 mg/kg of body weight administered every 12 h for 7 to 10 days eliminated cultivable B. burgdorferi or B. turicatae from all BALB/c or scid mice in the study. Vancomycin at 30 mg/kg administered every 12 h was effective in eliminating infection from immunodeficient mice if treatment was started within 3 days of the onset of infection. If treatment with vancomycin was delayed for 7 days or more, vancomycin failed to eradicate infection with B. burgdorferi or B. toricatae from immunodeficient mice. The failure of vancomycin in eradicating established infections in immunodeficient mice was associated with the persistence of viable spirochetes in the brain during antibiotic treatment.

Original languageEnglish (US)
Pages (from-to)2632-2636
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume40
Issue number11
StatePublished - Nov 1996

Fingerprint

Borrelia
Ceftriaxone
Vancomycin
Borrelia burgdorferi
Brain
Infection
Relapsing Fever
Spirochaetales
Lyme Disease
Body Weight
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Kazragis, R. J., Dever, L. L., Jorgensen, J. H., & Barbour, A. G. (1996). In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites. Antimicrobial Agents and Chemotherapy, 40(11), 2632-2636.

In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites. / Kazragis, Robert J.; Dever, Lisa L.; Jorgensen, James H.; Barbour, Alan G.

In: Antimicrobial Agents and Chemotherapy, Vol. 40, No. 11, 11.1996, p. 2632-2636.

Research output: Contribution to journalArticle

Kazragis, RJ, Dever, LL, Jorgensen, JH & Barbour, AG 1996, 'In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites', Antimicrobial Agents and Chemotherapy, vol. 40, no. 11, pp. 2632-2636.
Kazragis, Robert J. ; Dever, Lisa L. ; Jorgensen, James H. ; Barbour, Alan G. / In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites. In: Antimicrobial Agents and Chemotherapy. 1996 ; Vol. 40, No. 11. pp. 2632-2636.
@article{b7095ab7bed44ea195b60d804f7b970c,
title = "In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites",
abstract = "Borrelia burgdorferi, the agent of Lyme disease, and B. toricatae, a neurotropic agent of relapsing fever, are susceptible to vancomycin in vitro, with an MIC of 0.5 μg/ml. To determine the activity of vancomycin in vivo, particularly in the brain, we infected adult immunocompetent BALB/c and immunodeficient CB-17 scid mice with B. burgdorferi or B. turicatae. The mice were then treated with vancomycin, ceftriaxone as a positive control, or normal saline as a negative control. The effectiveness of treatment was assessed by cultures of blood and brain and other tissues. Ceftriaxone at a dose of 25 mg/kg of body weight administered every 12 h for 7 to 10 days eliminated cultivable B. burgdorferi or B. turicatae from all BALB/c or scid mice in the study. Vancomycin at 30 mg/kg administered every 12 h was effective in eliminating infection from immunodeficient mice if treatment was started within 3 days of the onset of infection. If treatment with vancomycin was delayed for 7 days or more, vancomycin failed to eradicate infection with B. burgdorferi or B. toricatae from immunodeficient mice. The failure of vancomycin in eradicating established infections in immunodeficient mice was associated with the persistence of viable spirochetes in the brain during antibiotic treatment.",
author = "Kazragis, {Robert J.} and Dever, {Lisa L.} and Jorgensen, {James H.} and Barbour, {Alan G.}",
year = "1996",
month = "11",
language = "English (US)",
volume = "40",
pages = "2632--2636",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites

AU - Kazragis, Robert J.

AU - Dever, Lisa L.

AU - Jorgensen, James H.

AU - Barbour, Alan G.

PY - 1996/11

Y1 - 1996/11

N2 - Borrelia burgdorferi, the agent of Lyme disease, and B. toricatae, a neurotropic agent of relapsing fever, are susceptible to vancomycin in vitro, with an MIC of 0.5 μg/ml. To determine the activity of vancomycin in vivo, particularly in the brain, we infected adult immunocompetent BALB/c and immunodeficient CB-17 scid mice with B. burgdorferi or B. turicatae. The mice were then treated with vancomycin, ceftriaxone as a positive control, or normal saline as a negative control. The effectiveness of treatment was assessed by cultures of blood and brain and other tissues. Ceftriaxone at a dose of 25 mg/kg of body weight administered every 12 h for 7 to 10 days eliminated cultivable B. burgdorferi or B. turicatae from all BALB/c or scid mice in the study. Vancomycin at 30 mg/kg administered every 12 h was effective in eliminating infection from immunodeficient mice if treatment was started within 3 days of the onset of infection. If treatment with vancomycin was delayed for 7 days or more, vancomycin failed to eradicate infection with B. burgdorferi or B. toricatae from immunodeficient mice. The failure of vancomycin in eradicating established infections in immunodeficient mice was associated with the persistence of viable spirochetes in the brain during antibiotic treatment.

AB - Borrelia burgdorferi, the agent of Lyme disease, and B. toricatae, a neurotropic agent of relapsing fever, are susceptible to vancomycin in vitro, with an MIC of 0.5 μg/ml. To determine the activity of vancomycin in vivo, particularly in the brain, we infected adult immunocompetent BALB/c and immunodeficient CB-17 scid mice with B. burgdorferi or B. turicatae. The mice were then treated with vancomycin, ceftriaxone as a positive control, or normal saline as a negative control. The effectiveness of treatment was assessed by cultures of blood and brain and other tissues. Ceftriaxone at a dose of 25 mg/kg of body weight administered every 12 h for 7 to 10 days eliminated cultivable B. burgdorferi or B. turicatae from all BALB/c or scid mice in the study. Vancomycin at 30 mg/kg administered every 12 h was effective in eliminating infection from immunodeficient mice if treatment was started within 3 days of the onset of infection. If treatment with vancomycin was delayed for 7 days or more, vancomycin failed to eradicate infection with B. burgdorferi or B. toricatae from immunodeficient mice. The failure of vancomycin in eradicating established infections in immunodeficient mice was associated with the persistence of viable spirochetes in the brain during antibiotic treatment.

UR - http://www.scopus.com/inward/record.url?scp=0029910035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029910035&partnerID=8YFLogxK

M3 - Article

C2 - 8913478

AN - SCOPUS:0029910035

VL - 40

SP - 2632

EP - 2636

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -